Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65.


Journal

Urology practice
ISSN: 2352-0787
Titre abrégé: Urol Pract
Pays: United States
ID NLM: 101635343

Informations de publication

Date de publication:
01 2023
Historique:
medline: 1 5 2023
pubmed: 27 4 2023
entrez: 27 4 2023
Statut: ppublish

Résumé

Medicare eligibility at 65 has been associated with increased diagnosis and survival for certain cancers due to greater health care utilization. We aim to assess for a similar "Medicare effect" for bladder and kidney cancers, which has not been previously established. Patients diagnosed with bladder or kidney cancer from 2000-2018 at ages 60-69 years were identified with the Surveillance, Epidemiology, and End Results database. We used age-over-age percent change calculations to characterize trends in cancer diagnoses focusing on patients aged 65. Multivariable Cox models were used to compare cancer-specific mortality across ages at diagnosis. We identified 63,960 patients diagnosed with bladder cancer and 52,316 diagnosed with kidney cancer. Age-over-age change in diagnosis was highest for patients aged 65 compared to all other ages for both cancers ( The age of 65, marking the onset of Medicare eligibility, is associated with more diagnoses of bladder and kidney cancer. Patients diagnosed at age 65 demonstrate decreased bladder and kidney cancer-specific mortality.

Identifiants

pubmed: 37103437
doi: 10.1097/UPJ.0000000000000351
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-65

Auteurs

Timothy D Shu (TD)

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Case Western Reserve University School of Medicine, Cleveland, Ohio.

Megan C Prunty (MC)

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Case Western Reserve University School of Medicine, Cleveland, Ohio.

Raymond Pominville (R)

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Case Western Reserve University School of Medicine, Cleveland, Ohio.

Danly Omil-Lima (D)

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Case Western Reserve University School of Medicine, Cleveland, Ohio.

Alberto A Castro Bigalli (AA)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Alexander Kutikov (A)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Laura Bukavina (L)

Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Adam C Calaway (AC)

Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Case Western Reserve University School of Medicine, Cleveland, Ohio.

Sarah C Markt (SC)

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH